Inno-206

Delirium

University of WashingtonN/AActive

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 89/ 100

Competitive context

8 Active assets in the Delirium cohort.

Asset / Sponsor	Phase	Rating
Amantadine Methodist Rehabilitation Center	Phase 4	BB
Suvorexant Mayo Clinic	Phase 4	BB
SUFENTANYL Peking University First Hospital	Phase 4	BB
ZIPRASIDONE George Washington University	Phase 4	BB
DEXAMETHASONE Peking University First Hospital	Phase 4	BB

View all 14 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

77 / 100

plasma cell myelomaDormant

BBB

Indicative ·

77 / 100

Recurrent Adult Acute Lymphoblastic LeukemiaDormant

BBB

Indicative ·

77 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.